Taser International (TASR) shares edged higher in early trading on Thursday after the electric weapons company announced multiple large orders of its AXON body-worn video cameras and EVIDENCE.com solution. The orders received are expected to ship in 4Q’14.
“We continue to see strong interest in our AXON body cameras and believe President Obama’s proposal for new funding for body cameras this week is a step in the right direction to helping improve relations between police officers and communities,” Rick Smith, CEO & Founder of TASER International said in a statement. “There are approximately 750,000 active sworn officers in the US and we believe every one of them should be issued a body camera along with their badge and weapon.”
Taser Int’l Inc. is up $0.59, or 2.80%, to $23.45 in pre-market trading. On valuation-measures, the name has a trailing-12 and forward P/E of 61.78 and 48.64, respectively. P/E to growth ratio is 1.92, while t-12 profit margin is 12.81%. EPS registers at $0.37. The company has a market cap of $1.20B and a median Wall Street price target of $22.00 with a high target of $24.00.
On trading-measures, TASR has a beta of (0.46) and a short float of 17.90%. In the past 52 weeks, shares of Scottsdale, Arizona-based company have traded between a low of $10.46 and a high of $24.44 with the 50-day MA and 200-day MA located at $18.51 and $15.14 levels, respectively.
TASR currently prints a one year return of about 32.98% and a year-to-date return of around 43.95%.
Array BioPharma, Inc. (ARRY) shares soared 24.55% on Thursday in pre-market trading after the company announced that it has reached an agreement with Novartis International Pharma (NVS) to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials.
“Regaining full worldwide rights to binimetinib, an innovative late-stage oncology product, represents a tremendous opportunity for Array,” said Ron Squarer, Chief Executive Officer, Array BioPharma. “Binimetinib is currently advancing in three Phase 3 clinical trials and, we expect to file for our first regulatory approval during the first half of 2016…”
Array BioPharma, Inc., currently valued at $515.98M, has a median Wall Street price target of $7.00 with a high target of $9.00. In the past 12 months, shares of Boulder, Colorado-based biopharmaceutical firm have traded between a low of $2.98 and a high of $6.05 with the 50-day MA and 200-day MA located at $3.70 and $3.90 levels, respectively. Additionally, shares of ARRY trade at a P/E ratio of -0.54 and have a Relative Strength Index (RSI) and MACD indicator of 55.82 and +0.12, respectively.
ARRY currently prints a year-over-year loss of around 34.72%%, compared with a 16.21% gain in the S&P 500.
Plug Power (PLUG)’s stock surged more than 12% in premarket trade Thursday, after the company announced a contract valued at $20 million for its ReliOn integrated fuel cell solution and GenFuel hydrogen services to be used with a “major North American telecommunications provider.”
On valuation measures, Plug Power has a price/sales and price/book of 11.93 and 3.70, respectively. EPS is ($0.78). Currently there are 2 analysts that rate PLUG a ‘Buy’, 1 rates it a ‘Hold’. No analyst rates it a ‘Sell’. PLUG has a median Wall Street price target of $6.50 with a high target of $8.00.
In the past 52 weeks, shares of Latham, New York-based company have traded between a low of $1.43 and a high of $11.72 and are now at $3.93.
Shares are up 343.04% year-over-year and 125.81% year-to-date.
Citigroup (C) weighed in on Mobileye N.V. (MBLY) this morning saying recent share pullback brings “compelling” entry point. Separately, MBLY was upgraded to ‘Buy’ from ‘Hold’ and given a $53, 12-month base case estimate at Deutsche Bank (DB).
DB’s new PT implies a 26.76% expected return vs a $41.81 close.
Mobileye shares recently gained $1.44 to $43.25. In the past 52 weeks the name has traded between a low of $31.11 and a high of $60.28, which is almost 94% above that low price. Ticker is up 13.00% year-to-date.